Form 4: Vericel Corp CEO Dominick Colangelo Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Dominick Colangelo, President and CEO of Vericel Corp, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 11 and 12, 2024, Dominick Colangelo, the President and CEO of Vericel Corp, exercised stock options to acquire 17,500 shares of common stock on each day at a price of $3.02 per share.
- Concurrently, Colangelo sold 17,500 shares of common stock on each day at prices of $43.37 and $43.90, respectively.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on September 1, 2023.
- Following these transactions, Colangelo directly owns 220,937 shares of Vericel Corp common stock.
- He also holds options to purchase 70,000 shares of common stock at an exercise price of $3.02, which expire on January 5, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions under a pre-arranged plan, which is a normal course of business.
Industry Context
Executive stock transactions are common and closely monitored, especially in publicly traded companies like Vericel Corp. The use of Rule 10b5-1 plans allows insiders to sell shares without being accused of trading on non-public information.
Comparison to Industry Standards
- Executive compensation packages often include stock options to align management's interests with those of shareholders.
- Rule 10b5-1 trading plans are a standard practice among corporate executives to diversify their holdings and manage personal finances while avoiding insider trading accusations.
- Companies like Amgen, Biogen, and Vertex Pharmaceuticals also see regular Form 4 filings from their executives related to stock option exercises and sales.
Stakeholder Impact
- Shareholders may view the transactions as part of the executive's personal financial planning.
- The transactions have a minimal impact on the company's operations or financial condition.
Key Dates
| Date | Description |
|---|---|
| January 5, 2015 | Date options were awarded, expiring on January 5, 2025. |
| April 5, 2015 | First vesting date of the options. |
| September 1, 2023 | Date the Rule 10b5-1 trading plan was adopted. |
| September 11, 2024 | Date of first reported transaction: exercise of options and sale of shares. |
| September 12, 2024 | Date of second reported transaction: exercise of options and sale of shares. |
| September 13, 2024 | Date of Form 4 filing. |
| January 5, 2025 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.